BetterLife Pharma Inc. announced a private placement to issue 10% convertible debentures for the gross proceeds of CAD 65,000 on March 4, 2024. The Convertible Debentures are convertible at the option of the holder into units of the Company, consisting of one common share and one share purchase warrant, at a conversion price of CAD 0.10 per unit. Each share purchase warrant will have an exercise price of CAD 0.10 and will expire on August 31, 2026.

The debentures bear 10% interest rate and matures on February 28, 2026.